CN103874690B

CN103874690B - 含酰肼的核运输调节剂及其用途

含酰肼的核运输调节剂及其用途 Download PDF

Info

Publication number: CN103874690B
Authority: CN; China
Prior art keywords: compound; formula; trifluoromethyl; phenyl; double
Prior art date: 2011-07-29
Legal status : Active

Application number

CN201280047939.2A

Other languages

English (en)

Other versions

CN103874690A (zh

Inventor

V·P·桑达纳亚卡

S·沙查姆

D·麦考利

S·谢克特尔

Current Assignee

Karyopharm Therapeutics Inc

Original Assignee

Karyopharm Therapeutics Inc

Priority date

2011-07-29

Filing date

2012-07-26

Publication date

2016-07-06

Priority claimed from US201161513432P external-priority

2012-07-26 Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc

2012-07-26 Priority to CN201610414957.XA priority Critical patent/CN106083827B/zh

2012-07-26 Priority to CN201910730981.8A priority patent/CN110372672A/zh

2012-07-26 Priority to CN201910734865.3A priority patent/CN110372673A/zh

2014-06-18 Publication of CN103874690A publication Critical patent/CN103874690A/zh

2016-07-06 Application granted granted Critical

2016-07-06 Publication of CN103874690B publication Critical patent/CN103874690B/zh

Status Active legal-status Critical Current

2032-07-26 Anticipated expiration legal-status Critical

Links

229940042795 Hydrazides for tuberculosis treatment Drugs 0.000 title description 39
150000001875 compounds Chemical class 0.000 claims abstract description 405
239000000203 mixture Substances 0.000 claims abstract description 193
239000011780 sodium chloride Substances 0.000 claims abstract description 78
150000003839 salts Chemical class 0.000 claims abstract description 65
102100014004 XPO1 Human genes 0.000 claims abstract description 51
108091004173 exportin 1 protein Proteins 0.000 claims abstract description 50
230000000694 effects Effects 0.000 claims abstract description 37
201000010099 disease Diseases 0.000 claims description 84
239000003814 drug Substances 0.000 claims description 61
201000011510 cancer Diseases 0.000 claims description 30
230000012010 growth Effects 0.000 claims description 11
210000001519 tissues Anatomy 0.000 claims description 11
230000002159 abnormal effect Effects 0.000 claims description 10
208000001756 Virus Disease Diseases 0.000 claims description 9
206010053643 Neurodegenerative disease Diseases 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
230000002062 proliferating Effects 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
230000037406 food intake Effects 0.000 claims description 6
206010003816 Autoimmune disease Diseases 0.000 claims description 5
235000012631 food intake Nutrition 0.000 claims description 5
200000000018 inflammatory disease Diseases 0.000 claims description 5
206010047461 Viral infection Diseases 0.000 claims description 4
230000017613 viral reproduction Effects 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 2
230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
238000003786 synthesis reaction Methods 0.000 abstract description 84
230000015572 biosynthetic process Effects 0.000 abstract description 81
230000002194 synthesizing Effects 0.000 abstract description 79
230000002401 inhibitory effect Effects 0.000 abstract description 32
239000003112 inhibitor Substances 0.000 abstract description 16
238000006467 substitution reaction Methods 0.000 abstract description 4
230000002265 prevention Effects 0.000 abstract description 2
230000004962 physiological condition Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 190
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 119
-1 c-Ab1 Proteins 0.000 description 116
239000002585 base Substances 0.000 description 106
239000000376 reactant Substances 0.000 description 94
210000004027 cells Anatomy 0.000 description 92
235000019439 ethyl acetate Nutrition 0.000 description 83
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 82
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
239000000243 solution Substances 0.000 description 77
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 70
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 59
238000006243 chemical reaction Methods 0.000 description 56
238000000034 method Methods 0.000 description 56
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
229910052736 halogen Inorganic materials 0.000 description 47
IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
150000002367 halogens Chemical class 0.000 description 46
229910052757 nitrogen Inorganic materials 0.000 description 44
239000003513 alkali Substances 0.000 description 41
239000012071 phase Substances 0.000 description 40
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 38
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
206010006187 Breast cancer Diseases 0.000 description 37
239000000284 extract Substances 0.000 description 37
238000005160 1H NMR spectroscopy Methods 0.000 description 36
210000003739 Neck Anatomy 0.000 description 36
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 36
239000012141 concentrate Substances 0.000 description 35
239000007787 solid Substances 0.000 description 33
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
239000012044 organic layer Substances 0.000 description 30
201000008275 breast carcinoma Diseases 0.000 description 27
229910052760 oxygen Inorganic materials 0.000 description 27
229910052938 sodium sulfate Inorganic materials 0.000 description 27
229910052717 sulfur Inorganic materials 0.000 description 27
206010028980 Neoplasm Diseases 0.000 description 26
FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 26
PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 26
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
241000700159 Rattus Species 0.000 description 25
125000001424 substituent group Chemical group 0.000 description 25
BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 24
241000699670 Mus sp. Species 0.000 description 24
238000004128 high performance liquid chromatography Methods 0.000 description 24
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 24
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 24
239000001301 oxygen Substances 0.000 description 24
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 24
229910052739 hydrogen Inorganic materials 0.000 description 23
230000000269 nucleophilic Effects 0.000 description 23
NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 23
239000011593 sulfur Substances 0.000 description 23
239000002253 acid Substances 0.000 description 22
239000001257 hydrogen Substances 0.000 description 22
239000000126 substance Substances 0.000 description 22
230000035492 administration Effects 0.000 description 21
239000012267 brine Substances 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
230000001629 suppression Effects 0.000 description 21
238000003756 stirring Methods 0.000 description 20
NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 19
239000000969 carrier Substances 0.000 description 19
239000008079 hexane Substances 0.000 description 19
210000004556 Brain Anatomy 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
239000007832 Na2SO4 Substances 0.000 description 18
125000001931 aliphatic group Chemical group 0.000 description 18
125000003118 aryl group Chemical group 0.000 description 18
239000000460 chlorine Substances 0.000 description 18
102000003945 NF-kappa B Human genes 0.000 description 17
108010057466 NF-kappa B Proteins 0.000 description 17
BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 17
125000004433 nitrogen atoms Chemical group N* 0.000 description 17
239000000047 product Substances 0.000 description 17
238000011160 research Methods 0.000 description 17
230000035533 AUC Effects 0.000 description 16
210000002381 Plasma Anatomy 0.000 description 16
238000004440 column chromatography Methods 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
102100019730 TP53 Human genes 0.000 description 15
101710026335 TP53 Proteins 0.000 description 15
230000037396 body weight Effects 0.000 description 15
229910052799 carbon Inorganic materials 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
230000001939 inductive effect Effects 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
239000011734 sodium Substances 0.000 description 15
238000007792 addition Methods 0.000 description 14
125000004432 carbon atoms Chemical group C* 0.000 description 14
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 14
230000002829 reduced Effects 0.000 description 14
150000001336 alkenes Chemical class 0.000 description 13
125000000623 heterocyclic group Chemical group 0.000 description 13
239000000523 sample Substances 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 12
125000000217 alkyl group Chemical group 0.000 description 12
125000005843 halogen group Chemical group 0.000 description 12
125000001072 heteroaryl group Chemical group 0.000 description 12
238000011068 load Methods 0.000 description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
YACHGFWEQXFSBS-RJXCBBHPSA-N Leptomycin Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 11
229910004730 OSO2 Inorganic materials 0.000 description 11
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 11
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 11
108090001123 antibodies Proteins 0.000 description 11
102000004965 antibodies Human genes 0.000 description 11
125000004429 atoms Chemical group 0.000 description 11
239000003153 chemical reaction reagent Substances 0.000 description 11
230000004054 inflammatory process Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000000725 suspension Substances 0.000 description 11
201000010874 syndrome Diseases 0.000 description 11
239000000225 tumor suppressor protein Substances 0.000 description 11
230000006907 apoptotic process Effects 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
125000004093 cyano group Chemical group *C#N 0.000 description 10
238000003818 flash chromatography Methods 0.000 description 10
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
230000004044 response Effects 0.000 description 10
206010061218 Inflammation Diseases 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
210000004940 Nucleus Anatomy 0.000 description 9
125000002521 alkyl halide group Chemical group 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000002552 dosage form Substances 0.000 description 9
230000003203 everyday Effects 0.000 description 9
230000014509 gene expression Effects 0.000 description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
125000004435 hydrogen atoms Chemical group [H]* 0.000 description 9
229910000041 hydrogen chloride Inorganic materials 0.000 description 9
230000002757 inflammatory Effects 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
150000007524 organic acids Chemical class 0.000 description 9
235000009518 sodium iodide Nutrition 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
239000002904 solvent Substances 0.000 description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
206010003246 Arthritis Diseases 0.000 description 8
0 CC=*C(c1cc(*)cc(*)c1)=*C Chemical compound CC=*C(c1cc(*)cc(*)c1)=*C 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
102000008379 I-kappa B Proteins Human genes 0.000 description 8
108010021699 I-kappa B Proteins Proteins 0.000 description 8
UORVCLMRJXCDCP-UHFFFAOYSA-N Propiolic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 8
229940083599 Sodium Iodide Drugs 0.000 description 8
QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical class NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 8
230000002917 arthritic Effects 0.000 description 8
229910052681 coesite Inorganic materials 0.000 description 8
230000001808 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
229910052906 cristobalite Inorganic materials 0.000 description 8
239000005457 ice water Substances 0.000 description 8
239000010410 layer Substances 0.000 description 8
239000002609 media Substances 0.000 description 8
230000001613 neoplastic Effects 0.000 description 8
239000003921 oil Substances 0.000 description 8
NHOLWHQNCDTEHC-ARJAWSKDSA-N propan-2-yl (Z)-3-iodoprop-2-enoate Chemical compound CC(C)OC(=O)\C=C/I NHOLWHQNCDTEHC-ARJAWSKDSA-N 0.000 description 8
238000000746 purification Methods 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
229910052904 quartz Inorganic materials 0.000 description 8
239000000377 silicon dioxide Substances 0.000 description 8
239000002002 slurry Substances 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
229910052682 stishovite Inorganic materials 0.000 description 8
239000000758 substrate Substances 0.000 description 8
229910052905 tridymite Inorganic materials 0.000 description 8
238000005406 washing Methods 0.000 description 8
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 7
108091009013 9-cis retinoic acid receptor activity proteins Proteins 0.000 description 7
206010059512 Apoptosis Diseases 0.000 description 7
229940088598 Enzyme Drugs 0.000 description 7
229940079593 drugs Drugs 0.000 description 7
229910052731 fluorine Inorganic materials 0.000 description 7
235000019253 formic acid Nutrition 0.000 description 7
230000036231 pharmacokinetics Effects 0.000 description 7
201000004681 psoriasis Diseases 0.000 description 7
102000034577 retinoid X receptors Human genes 0.000 description 7
XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
229910052710 silicon Inorganic materials 0.000 description 7
239000010703 silicon Substances 0.000 description 7
230000002103 transcriptional Effects 0.000 description 7
230000032258 transport Effects 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
241000725619 Dengue virus Species 0.000 description 6
JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
108010066154 Nuclear Export Signals Proteins 0.000 description 6
TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 6
210000003491 Skin Anatomy 0.000 description 6
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000000240 adjuvant Effects 0.000 description 6
230000000903 blocking Effects 0.000 description 6
229910052801 chlorine Inorganic materials 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000007822 coupling agent Substances 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
230000001965 increased Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
229910052500 inorganic mineral Inorganic materials 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
230000001404 mediated Effects 0.000 description 6
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
235000010755 mineral Nutrition 0.000 description 6
239000011707 mineral Substances 0.000 description 6
230000003000 nontoxic Effects 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
238000005935 nucleophilic addition reaction Methods 0.000 description 6
XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
229910000073 phosphorus hydride Inorganic materials 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000002769 thiazolinyl group Chemical group 0.000 description 6
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
208000006673 Asthma Diseases 0.000 description 5
102000036638 BRCA1 Human genes 0.000 description 5
108010042977 BRCA1 Protein Proteins 0.000 description 5
210000004369 Blood Anatomy 0.000 description 5
206010008342 Cervix carcinoma Diseases 0.000 description 5
206010012310 Dengue fever Diseases 0.000 description 5
241000701806 Human papillomavirus Species 0.000 description 5
210000002510 Keratinocytes Anatomy 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
101700071021 SETD2 Proteins 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
239000008280 blood Substances 0.000 description 5
125000002837 carbocyclic group Chemical group 0.000 description 5
239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
230000002490 cerebral Effects 0.000 description 5
201000010881 cervical cancer Diseases 0.000 description 5
125000000753 cycloalkyl group Chemical group 0.000 description 5
YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
229910052805 deuterium Inorganic materials 0.000 description 5
238000003379 elimination reaction Methods 0.000 description 5
235000013305 food Nutrition 0.000 description 5
238000009169 immunotherapy Methods 0.000 description 5
238000001764 infiltration Methods 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000001603 reducing Effects 0.000 description 5
238000010992 reflux Methods 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
229960001866 silicon dioxide Drugs 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
239000001117 sulphuric acid Substances 0.000 description 5
235000011149 sulphuric acid Nutrition 0.000 description 5
VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
OEBXWWBYZJNKRK-UHFFFAOYSA-N 1-methyl-2,3,4,6,7,8-hexahydropyrimido[1,2-a]pyrimidine Chemical compound C1CCN=C2N(C)CCCN21 OEBXWWBYZJNKRK-UHFFFAOYSA-N 0.000 description 4
HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 4
210000001218 Blood-Brain Barrier Anatomy 0.000 description 4
101700067048 CDC13 Proteins 0.000 description 4
210000003169 Central Nervous System Anatomy 0.000 description 4
240000002694 Clidemia hirta Species 0.000 description 4
235000014277 Clidemia hirta Nutrition 0.000 description 4
210000000805 Cytoplasm Anatomy 0.000 description 4
206010048768 Dermatosis Diseases 0.000 description 4
229960003957 Dexamethasone Drugs 0.000 description 4
UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
241000668709 Dipterocarpus costatus Species 0.000 description 4
206010015548 Euthanasia Diseases 0.000 description 4
241000711549 Hepacivirus C Species 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
229940096397 Interleukin-8 Drugs 0.000 description 4
XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
102000004890 Interleukin-8 Human genes 0.000 description 4
108090001007 Interleukin-8 Proteins 0.000 description 4
206010023332 Keratitis Diseases 0.000 description 4
206010024324 Leukaemias Diseases 0.000 description 4
210000004185 Liver Anatomy 0.000 description 4
210000004072 Lung Anatomy 0.000 description 4
GSCCALZHGUWNJW-UHFFFAOYSA-N N-cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 4
210000000496 Pancreas Anatomy 0.000 description 4
241000219000 Populus Species 0.000 description 4
241000725643 Respiratory syncytial virus Species 0.000 description 4
208000006641 Skin Disease Diseases 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
WLPUWLXVBWGYMZ-UHFFFAOYSA-N Tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 4
JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
125000002723 alicyclic group Chemical group 0.000 description 4
230000001640 apoptogenic Effects 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
231100000599 cytotoxic agent Toxicity 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
235000013325 dietary fiber Nutrition 0.000 description 4
238000010790 dilution Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000001973 epigenetic Effects 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
150000002431 hydrogen Chemical group 0.000 description 4
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
229960001330 hydroxycarbamide Drugs 0.000 description 4
VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000011630 iodine Substances 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
150000007530 organic bases Chemical class 0.000 description 4
210000000056 organs Anatomy 0.000 description 4
201000008968 osteosarcoma Diseases 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
229920000306 polymethylpentene Polymers 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
RERYAUXONVNXSK-UHFFFAOYSA-N prop-2-enehydrazide;hydrochloride Chemical compound [Cl-].N[NH2+]C(=O)C=C RERYAUXONVNXSK-UHFFFAOYSA-N 0.000 description 4
OXXHZTDBNXEEFU-UHFFFAOYSA-N propan-2-yl prop-2-ynoate Chemical compound CC(C)OC(=O)C#C OXXHZTDBNXEEFU-UHFFFAOYSA-N 0.000 description 4
238000002626 targeted therapy Methods 0.000 description 4
230000001225 therapeutic Effects 0.000 description 4
YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
238000001262 western blot Methods 0.000 description 4
SOZGHDCEWOLLHV-UHFFFAOYSA-N 2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC=C1C#N SOZGHDCEWOLLHV-UHFFFAOYSA-N 0.000 description 3
WFKAJVHLWXSISD-UHFFFAOYSA-M 2-methylpropanimidate Chemical compound CC(C)C([O-])=N WFKAJVHLWXSISD-UHFFFAOYSA-M 0.000 description 3
TWVRAZXRYVXGHA-UHFFFAOYSA-N 3-propan-2-yloxy-5-(trifluoromethyl)benzonitrile Chemical compound CC(C)OC1=CC(C#N)=CC(C(F)(F)F)=C1 TWVRAZXRYVXGHA-UHFFFAOYSA-N 0.000 description 3
101710033782 75 Proteins 0.000 description 3
101700067675 A12 Proteins 0.000 description 3
206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
210000004204 Blood Vessels Anatomy 0.000 description 3
101710030634 COMMD1 Proteins 0.000 description 3
102000003952 Caspase 3 Human genes 0.000 description 3
108090000397 Caspase 3 Proteins 0.000 description 3
210000000078 Claw Anatomy 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
208000010412 Glaucoma Diseases 0.000 description 3
102100007188 HDAC5 Human genes 0.000 description 3
101700054126 HDAC5 Proteins 0.000 description 3
101700056516 HIF1 Proteins 0.000 description 3
102100003042 HIF1A Human genes 0.000 description 3
101700000053 HIF1A Proteins 0.000 description 3
208000006454 Hepatitis Diseases 0.000 description 3
102000003964 Histone deacetylases Human genes 0.000 description 3
108090000353 Histone deacetylases Proteins 0.000 description 3
241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
206010022114 Injury Diseases 0.000 description 3
208000002551 Irritable Bowel Syndrome Diseases 0.000 description 3
102100005665 KLF5 Human genes 0.000 description 3
101700051853 KLF5 Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
101710024180 MW0072 Proteins 0.000 description 3
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 3
230000036740 Metabolism Effects 0.000 description 3
206010061289 Metastatic neoplasm Diseases 0.000 description 3
206010029331 Neuropathy peripheral Diseases 0.000 description 3
108010077850 Nuclear Localization Signals Proteins 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
206010025310 Other lymphomas Diseases 0.000 description 3
101710040930 PTGS2 Proteins 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
240000005373 Panax quinquefolius Species 0.000 description 3
235000003140 Panax quinquefolius Nutrition 0.000 description 3
102000030951 Phosphotransferases Human genes 0.000 description 3
108091000081 Phosphotransferases Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
210000001525 Retina Anatomy 0.000 description 3
206010039073 Rheumatoid arthritis Diseases 0.000 description 3
241000315672 SARS coronavirus Species 0.000 description 3
208000009714 Severe Dengue Diseases 0.000 description 3
206010040767 Sjogren's syndrome Diseases 0.000 description 3
206010046736 Urticarias Diseases 0.000 description 3
101700061544 VP03 Proteins 0.000 description 3
238000010306 acid treatment Methods 0.000 description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
125000001118 alkylidene group Chemical group 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
235000019628 coolness Nutrition 0.000 description 3
238000005336 cracking Methods 0.000 description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
201000002950 dengue hemorrhagic fever Diseases 0.000 description 3
201000004624 dermatitis Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
101700031934 foxo Proteins 0.000 description 3
125000005842 heteroatoms Chemical group 0.000 description 3
125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
229940027318 hydroxyurea Drugs 0.000 description 3
230000001969 hypertrophic Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000002045 lasting Effects 0.000 description 3
239000011976 maleic acid Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000035786 metabolism Effects 0.000 description 3
230000001394 metastastic Effects 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
230000003287 optical Effects 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
201000007100 pharyngitis Diseases 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
IVRLZJDPKUSDCF-UHFFFAOYSA-N pyrazin-2-ylhydrazine Chemical compound NNC1=CN=CC=N1 IVRLZJDPKUSDCF-UHFFFAOYSA-N 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000001105 regulatory Effects 0.000 description 3
238000002390 rotary evaporation Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000001568 sexual Effects 0.000 description 3
201000007196 sexual disease Diseases 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000001384 succinic acid Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
229910052722 tritium Inorganic materials 0.000 description 3
229910052721 tungsten Inorganic materials 0.000 description 3
238000009423 ventilation Methods 0.000 description 3
230000003612 virological Effects 0.000 description 3
HVAYIAWJHRUOBC-UHFFFAOYSA-N (2,6-dimethylpyrimidin-4-yl)hydrazine Chemical compound CC1=CC(NN)=NC(C)=N1 HVAYIAWJHRUOBC-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-Hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
ZINDLWVBIZZAOY-UHFFFAOYSA-N 1-methyl-1-pyrazin-2-ylhydrazine Chemical compound CN(N)C1=CN=CC=N1 ZINDLWVBIZZAOY-UHFFFAOYSA-N 0.000 description 2
QLNFKVFUZHBVHT-UHFFFAOYSA-N 1-methyl-1-pyridin-2-ylhydrazine Chemical compound CN(N)C1=CC=CC=N1 QLNFKVFUZHBVHT-UHFFFAOYSA-N 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 2
101700027111 3SA0 Proteins 0.000 description 2
JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
206010000496 Acne Diseases 0.000 description 2
206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
206010001488 Aggression Diseases 0.000 description 2
WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
208000003455 Anaphylaxis Diseases 0.000 description 2
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
206010003402 Arthropod sting Diseases 0.000 description 2
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
108010005144 Bevacizumab Proteins 0.000 description 2
206010006448 Bronchiolitis Diseases 0.000 description 2
206010006451 Bronchitis Diseases 0.000 description 2
102100010655 COMMD1 Human genes 0.000 description 2
HUCVOHYBFXVBRW-UHFFFAOYSA-M Caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
206010009887 Colitis Diseases 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010011401 Crohn's disease Diseases 0.000 description 2
108050006400 Cyclins Proteins 0.000 description 2
102000016736 Cyclins Human genes 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
229960000640 Dactinomycin Drugs 0.000 description 2
229960000975 Daunorubicin Drugs 0.000 description 2
206010011878 Deafness Diseases 0.000 description 2
208000001490 Dengue Diseases 0.000 description 2
206010012434 Dermatitis allergic Diseases 0.000 description 2
102100016369 E2F4 Human genes 0.000 description 2
101700075173 E2F4 Proteins 0.000 description 2
101700028671 E2FA Proteins 0.000 description 2
101700025368 ERBB2 Proteins 0.000 description 2
102100016662 ERBB2 Human genes 0.000 description 2
206010014801 Endophthalmitis Diseases 0.000 description 2
PAMCRRDMORMCSM-UHFFFAOYSA-M FC(F)(F)[N-]C(=O)C1=CC=CC=C1 Chemical compound FC(F)(F)[N-]C(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-M 0.000 description 2
102100007155 FGF1 Human genes 0.000 description 2
101700064732 FGF1 Proteins 0.000 description 2
108050007372 Fibroblast growth factor family Proteins 0.000 description 2
102000018233 Fibroblast growth factor family Human genes 0.000 description 2
210000002683 Foot Anatomy 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
208000004898 Herpes Labialis Diseases 0.000 description 2
102000003893 Histone Acetyltransferases Human genes 0.000 description 2
108090000246 Histone Acetyltransferases Proteins 0.000 description 2
229940088597 Hormone Drugs 0.000 description 2
206010022000 Influenza Diseases 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
206010061255 Ischaemia Diseases 0.000 description 2
210000001847 Jaw Anatomy 0.000 description 2
210000003734 Kidney Anatomy 0.000 description 2
TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
239000005517 L01XE01 - Imatinib Substances 0.000 description 2
239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
208000001344 Macular Edema Diseases 0.000 description 2
206010025415 Macular oedema Diseases 0.000 description 2
229940091250 Magnesium supplements Drugs 0.000 description 2
210000002264 Mammary Glands, Animal Anatomy 0.000 description 2
210000004293 Mammary Glands, Human Anatomy 0.000 description 2
229960004961 Mechlorethamine Drugs 0.000 description 2
HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
210000003205 Muscles Anatomy 0.000 description 2
SXDVOLOHHWUQPJ-UHFFFAOYSA-N N-(trifluoromethyl)benzenecarbothioamide Chemical class FC(F)(F)NC(=S)C1=CC=CC=C1 SXDVOLOHHWUQPJ-UHFFFAOYSA-N 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
210000001331 Nose Anatomy 0.000 description 2
208000003435 Optic Neuritis Diseases 0.000 description 2
102100015381 PTGS2 Human genes 0.000 description 2
206010061536 Parkinson's disease Diseases 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000048284 Potato virus P Species 0.000 description 2
208000005069 Pulmonary Fibrosis Diseases 0.000 description 2
VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
102100000940 SETD2 Human genes 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
229940034785 Sutent Drugs 0.000 description 2
108060008443 TPPP Proteins 0.000 description 2
208000001106 Takayasu Arteritis Diseases 0.000 description 2
MODVSQKJJIBWPZ-VLLPJHQWSA-N Tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 2
229950009016 Tesetaxel Drugs 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
229960001727 Tretinoin Drugs 0.000 description 2
SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
108091007928 VEGF receptors Proteins 0.000 description 2
102100015249 VEGFA Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
101700035284 YLPM1 Proteins 0.000 description 2
102100014233 ZC3HAV1 Human genes 0.000 description 2
101710027492 ZC3HAV1 Proteins 0.000 description 2
230000003213 activating Effects 0.000 description 2
150000001263 acyl chlorides Chemical class 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229960001445 alitretinoin Drugs 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000036783 anaphylactic response Effects 0.000 description 2
230000003042 antagnostic Effects 0.000 description 2
230000002424 anti-apoptotic Effects 0.000 description 2
230000000118 anti-eoplastic Effects 0.000 description 2
230000000259 anti-tumor Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
201000001320 atherosclerosis Diseases 0.000 description 2
201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
150000003851 azoles Chemical class 0.000 description 2
210000000270 basal cell Anatomy 0.000 description 2
229960000397 bevacizumab Drugs 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
239000006143 cell culture media Substances 0.000 description 2
230000005591 charge neutralization Effects 0.000 description 2
239000012320 chlorinating reagent Substances 0.000 description 2
229960001411 chlormethine Drugs 0.000 description 2
230000001684 chronic Effects 0.000 description 2
229960004106 citric acid Drugs 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
101700067609 ctx Proteins 0.000 description 2
230000001086 cytosolic Effects 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
201000002949 dengue disease Diseases 0.000 description 2
231100000406 dermatitis Toxicity 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000009910 diseases by infectious agent Diseases 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
238000000132 electrospray ionisation Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
201000009273 endometriosis Diseases 0.000 description 2
102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 2
108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 2
238000001914 filtration Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000002496 gastric Effects 0.000 description 2
230000002068 genetic Effects 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000005556 hormone Substances 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
229960002411 imatinib Drugs 0.000 description 2
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000002318 immunoblotting Methods 0.000 description 2
230000001976 improved Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000003780 insertion Methods 0.000 description 2
201000010666 keratoconjunctivitis Diseases 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
201000010230 macular retinal edema Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000003211 malignant Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
108010045030 monoclonal antibodies Proteins 0.000 description 2
102000005614 monoclonal antibodies Human genes 0.000 description 2
239000010413 mother solution Substances 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
230000001537 neural Effects 0.000 description 2
230000001264 neutralization Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
201000001539 ovarian carcinoma Diseases 0.000 description 2
150000003891 oxalate salts Chemical class 0.000 description 2
230000002093 peripheral Effects 0.000 description 2
239000012466 permeate Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000000865 phosphorylative Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000003449 preventive Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
102000003998 progesterone receptors Human genes 0.000 description 2
108090000468 progesterone receptors Proteins 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
230000002797 proteolythic Effects 0.000 description 2
NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 2
QIEQDFYXVYQLLU-UHFFFAOYSA-N pyrimidin-4-ylhydrazine Chemical compound NNC1=CC=NC=N1 QIEQDFYXVYQLLU-UHFFFAOYSA-N 0.000 description 2
125000000719 pyrrolidinyl group Chemical class 0.000 description 2
GULVDPYLWVXKGC-UHFFFAOYSA-N quinoxalin-2-ylhydrazine Chemical compound C1=CC=CC2=NC(NN)=CN=C21 GULVDPYLWVXKGC-UHFFFAOYSA-N 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
201000010174 renal carcinoma Diseases 0.000 description 2
230000000268 renotropic Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000035939 shock Effects 0.000 description 2
231100000486 side effect Toxicity 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012453 solvate Substances 0.000 description 2
229960003787 sorafenib Drugs 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
229960001796 sunitinib Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000004083 survival Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
229960001367 tartaric acid Drugs 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
MUQNAPSBHXFMHT-UHFFFAOYSA-N tert-butylhydrazine Chemical compound CC(C)(C)NN MUQNAPSBHXFMHT-UHFFFAOYSA-N 0.000 description 2
150000003512 tertiary amines Chemical class 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
230000000699 topical Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000035897 transcription Effects 0.000 description 2
102000003995 transcription factors Human genes 0.000 description 2
108090000464 transcription factors Proteins 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
150000003852 triazoles Chemical group 0.000 description 2
210000004881 tumor cells Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
201000006704 ulcerative colitis Diseases 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 2
229940070710 valerate Drugs 0.000 description 2
229910052720 vanadium Inorganic materials 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000003442 weekly Effects 0.000 description 2
ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
NOTCVZXATRYXPI-UHFFFAOYSA-N (2-chloropyrimidin-4-yl)hydrazine Chemical compound NNC1=CC=NC(Cl)=N1 NOTCVZXATRYXPI-UHFFFAOYSA-N 0.000 description 1
CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
PNVWNMCAGZBUNK-UHFFFAOYSA-N (5-methylpyridin-2-yl)hydrazine Chemical compound CC1=CC=C(NN)N=C1 PNVWNMCAGZBUNK-UHFFFAOYSA-N 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
NYXYZCSAJZLFEH-UHFFFAOYSA-N (6-chloropyrimidin-4-yl)hydrazine Chemical compound NNC1=CC(Cl)=NC=N1 NYXYZCSAJZLFEH-UHFFFAOYSA-N 0.000 description 1
KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
IBFDLVHJHUMSAC-UPHRSURJSA-N (Z)-3-iodoprop-2-enoic acid Chemical compound OC(=O)\C=C/I IBFDLVHJHUMSAC-UPHRSURJSA-N 0.000 description 1
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
KDKYADYSIPSCCQ-UHFFFAOYSA-N 1-Butyne Chemical group CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
DLSSJBVOUGLFKC-UHFFFAOYSA-N 1-methyl-1-(3-methylpyridin-2-yl)hydrazine Chemical compound CN(N)C1=NC=CC=C1C DLSSJBVOUGLFKC-UHFFFAOYSA-N 0.000 description 1
QWXDABYFPHXDEY-UHFFFAOYSA-N 1-methyl-1-pyridin-3-ylhydrazine Chemical compound CN(N)C1=CC=CN=C1 QWXDABYFPHXDEY-UHFFFAOYSA-N 0.000 description 1
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
ZVJHJDDKYZXRJI-UHFFFAOYSA-N 1-pyrroline Chemical compound C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
BYHVGQHIAFURIL-UHFFFAOYSA-N 2-chloroquinoxaline Chemical compound C1=CC=CC2=NC(Cl)=CN=C21 BYHVGQHIAFURIL-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
MTPJEFOSTIKRSS-UHFFFAOYSA-N 3-(dimethylamino)propanenitrile Chemical compound CN(C)CCC#N MTPJEFOSTIKRSS-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
AYNUKEDZAYOEGG-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzonitrile Chemical compound FC1=CC(C#N)=CC(C(F)(F)F)=C1 AYNUKEDZAYOEGG-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ADHLSOGCYJHJBG-UHFFFAOYSA-N 4-[5-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1,3-dihydrobenzimidazol-2-ylidene]cyclohexa-2,5-dien-1-one Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(NC4=CC=3)=C3C=CC(=O)C=C3)C2=C1 ADHLSOGCYJHJBG-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
VLNHDKDBGWXJEE-GYHUNEDQSA-N 5'-Guanidinonaltrindole Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C=5NC6=CC=C(C=C6C=5C[C@]2(O)[C@]34CC1)NC(=N)N)CC1CC1 VLNHDKDBGWXJEE-GYHUNEDQSA-N 0.000 description 1
BRULKRUQKPEQRF-UHFFFAOYSA-N 5-[3-propan-2-yloxy-5-(trifluoromethyl)phenyl]-1H-1,2,4-triazole Chemical class FC(F)(F)C1=CC(OC(C)C)=CC(C2=NNC=N2)=C1 BRULKRUQKPEQRF-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
102100001249 ALB Human genes 0.000 description 1
VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
102100018024 ANG Human genes 0.000 description 1
102100004600 ANXA2 Human genes 0.000 description 1
101700001858 ANXA2 Proteins 0.000 description 1
229960003272 ASPARAGINASE Drugs 0.000 description 1
229960004176 Aclarubicin Drugs 0.000 description 1
RJURFGZVJUQBHK-UHFFFAOYSA-N Actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 1
206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
208000009956 Adenocarcinoma Diseases 0.000 description 1
206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
208000002353 Alcoholic Hepatitis Diseases 0.000 description 1
206010001627 Alcoholic liver disease Diseases 0.000 description 1
108010090838 Alemtuzumab Proteins 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
229950010817 Alvocidib Drugs 0.000 description 1
206010001897 Alzheimer's disease Diseases 0.000 description 1
229960003896 Aminopterin Drugs 0.000 description 1
229960001220 Amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
206010002023 Amyloidosis Diseases 0.000 description 1
206010002022 Amyloidosis Diseases 0.000 description 1
108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 description 1
206010002027 Amyotrophy Diseases 0.000 description 1
OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010002383 Angina pectoris Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
206010002556 Ankylosing spondylitis Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
208000002399 Aphthous Stomatitis Diseases 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
206010003230 Arteritis Diseases 0.000 description 1
229940072107 Ascorbate Drugs 0.000 description 1
208000006740 Aseptic Meningitis Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
229940009098 Aspartate Drugs 0.000 description 1
MOTJMGVDPWRKOC-QPVYNBJUSA-N Atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
230000037173 Auc Inf Effects 0.000 description 1
210000003719 B-Lymphocytes Anatomy 0.000 description 1
108010000750 BRCA2 Protein Proteins 0.000 description 1
102000002280 BRCA2 Protein Human genes 0.000 description 1
241001536481 Banzi virus Species 0.000 description 1
208000009137 Behcet Syndrome Diseases 0.000 description 1
201000008335 Behcet's disease Diseases 0.000 description 1
LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
229950011276 Belotecan Drugs 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
229960001561 Bleomycin Drugs 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000010217 Blepharitis Diseases 0.000 description 1
201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
210000000988 Bone and Bones Anatomy 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
210000000133 Brain Stem Anatomy 0.000 description 1
210000000481 Breast Anatomy 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
208000000594 Bullous Pemphigoid Diseases 0.000 description 1
208000009899 Burkitt Lymphoma Diseases 0.000 description 1
ZLDCAHDWVHDZMV-IHWYPQMZSA-N CC1C(c2n[n](/C=C\C(O)=O)cn2)=CC(C(F)(F)F)=CC1C(F)(F)F Chemical compound CC1C(c2n[n](/C=C\C(O)=O)cn2)=CC(C(F)(F)F)=CC1C(F)(F)F ZLDCAHDWVHDZMV-IHWYPQMZSA-N 0.000 description 1
KPZDRLRXWOMBAM-GEUSGDSSSA-N CC1N=CC(NCNC(/C=C\N/N=C(/c(cc2C(F)(F)F)cc(C(F)(F)F)c2Cl)\N=C/C)=O)=NC1 Chemical compound CC1N=CC(NCNC(/C=C\N/N=C(/c(cc2C(F)(F)F)cc(C(F)(F)F)c2Cl)\N=C/C)=O)=NC1 KPZDRLRXWOMBAM-GEUSGDSSSA-N 0.000 description 1
VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N CN(C)\N=N\c1[nH]cnc1C(N)=O Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
102100016705 COL18A1 Human genes 0.000 description 1
FELYUDXFXXOMRR-ADFTVYSNSA-N C[C@H](CC1CC(F)(F)F)[C@]1(C)/C=C/C(F)(F)F Chemical compound C[C@H](CC1CC(F)(F)F)[C@]1(C)/C=C/C(F)(F)F FELYUDXFXXOMRR-ADFTVYSNSA-N 0.000 description 1
DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
229960000846 Camphor Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229950005953 Camsilate Drugs 0.000 description 1
229960004117 Capecitabine Drugs 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
229960004562 Carboplatin Drugs 0.000 description 1
SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000005846 Cardiomyopathy Diseases 0.000 description 1
208000005024 Castleman Disease Diseases 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
102000005483 Cell Cycle Proteins Human genes 0.000 description 1
108010031896 Cell Cycle Proteins Proteins 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
210000003679 Cervix Uteri Anatomy 0.000 description 1
108010022830 Cetuximab Proteins 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
229960004630 Chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229940107161 Cholesterol Drugs 0.000 description 1
206010063118 Chorioretinopathy Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
208000007451 Chronic Bronchitis Diseases 0.000 description 1
206010008909 Chronic hepatitis Diseases 0.000 description 1
206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 1
235000007516 Chrysanthemum Nutrition 0.000 description 1
240000005250 Chrysanthemum indicum Species 0.000 description 1
235000005986 Chrysanthemum x morifolium Nutrition 0.000 description 1
229950004783 Cipionate Drugs 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
206010010619 Congenital rubella infection Diseases 0.000 description 1
206010010736 Conjunctival ulcer Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000010247 Contact Dermatitis Diseases 0.000 description 1
208000002077 Coxsackievirus Infections Diseases 0.000 description 1
208000008208 Craniocerebral Trauma Diseases 0.000 description 1
206010070976 Craniocerebral injury Diseases 0.000 description 1
229950006799 Crisantaspase Drugs 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
208000010342 Crystal Arthropathy Diseases 0.000 description 1
206010061419 Crystal arthropathy Diseases 0.000 description 1
240000006954 Cunninghamia lanceolata Species 0.000 description 1
102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 1
108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 1
102000015550 Cyclin-dependent kinase inhibitor Human genes 0.000 description 1
108050004829 Cyclin-dependent kinase inhibitor Proteins 0.000 description 1
206010011715 Cyclitis Diseases 0.000 description 1
229960004397 Cyclophosphamide Drugs 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101700070526 DNMT1 Proteins 0.000 description 1
XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
NNJPGOLRFBJNIW-HNNXBMFYSA-N Demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012601 Diabetes mellitus Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
241001475178 Dira Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
229960001904 EPIRUBICIN Drugs 0.000 description 1
210000003981 Ectoderm Anatomy 0.000 description 1
208000005679 Eczema Diseases 0.000 description 1
108010070635 Edrecolomab Proteins 0.000 description 1
BNFRJXLZYUTIII-UHFFFAOYSA-N Efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
229950002339 Elsamitrucin Drugs 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
210000003725 Endotheliocyte Anatomy 0.000 description 1
206010067410 Endotoxaemia Diseases 0.000 description 1
229940095399 Enema Drugs 0.000 description 1
241000792859 Enema Species 0.000 description 1
SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
229950011487 Enocitabine Drugs 0.000 description 1
206010015084 Episcleritis Diseases 0.000 description 1
210000003743 Erythrocytes Anatomy 0.000 description 1
229950007655 Esilate Drugs 0.000 description 1
229960001842 Estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
OLAMWIPURJGSKE-UHFFFAOYSA-N Et2O diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
XYIBRDXRRQCHLP-UHFFFAOYSA-N Ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
UMILHIMHKXVDGH-UHFFFAOYSA-N Etoglucid Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
229960005237 Etoglucid Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 Etoposide Drugs 0.000 description 1
230000036826 Excretion Effects 0.000 description 1
230000036081 Excretion rate Effects 0.000 description 1
210000002744 Extracellular Matrix Anatomy 0.000 description 1
210000003414 Extremities Anatomy 0.000 description 1
206010015993 Eyelid oedema Diseases 0.000 description 1
102100006141 FOXA2 Human genes 0.000 description 1
101700049079 FOXA2 Proteins 0.000 description 1
208000009760 Familial Amyloid Neuropathy Diseases 0.000 description 1
208000000336 Familial Exudative Vitreoretinopathy Diseases 0.000 description 1
206010064570 Familial cold autoinflammatory syndrome Diseases 0.000 description 1
206010016207 Familial mediterranean fever Diseases 0.000 description 1
KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
208000001362 Fetal Growth Retardation Diseases 0.000 description 1
229960002949 Fluorouracil Drugs 0.000 description 1
206010070531 Foetal growth restriction Diseases 0.000 description 1
229960000304 Folic Acid Drugs 0.000 description 1
229960002598 Fumaric acid Drugs 0.000 description 1
229960001731 GLUCEPTATE Drugs 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
108010091266 Gemtuzumab Proteins 0.000 description 1
210000002816 Gills Anatomy 0.000 description 1
229940080856 Gleevec Drugs 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229960002449 Glycine Drugs 0.000 description 1
102100016430 HDAC4 Human genes 0.000 description 1
101700050702 HDAC4 Proteins 0.000 description 1
102100009498 HMGB1 Human genes 0.000 description 1
108010014739 HMGB1 Protein Proteins 0.000 description 1
102100009397 HTATIP2 Human genes 0.000 description 1
101710040219 HTATIP2 Proteins 0.000 description 1
210000003128 Head Anatomy 0.000 description 1
206010019233 Headache Diseases 0.000 description 1
208000004559 Hearing Loss Diseases 0.000 description 1
206010011879 Hearing loss Diseases 0.000 description 1
208000005209 Hematologic Disease Diseases 0.000 description 1
206010019641 Hepatic cirrhosis Diseases 0.000 description 1
206010019668 Hepatic fibrosis Diseases 0.000 description 1
208000002672 Hepatitis B Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
229940022353 Herceptin Drugs 0.000 description 1
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes Zoster Diseases 0.000 description 1
HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
208000006572 Human Influenza Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006822 Human Serum Albumin Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000341655 Human papillomavirus type 16 Species 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
229940088013 Hycamtin Drugs 0.000 description 1
208000009576 Hypercholesterolemia Diseases 0.000 description 1
206010020630 Hypergammaglobulinaemia Diseases 0.000 description 1
206010020675 Hypermetropia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
101700086738 IORF Proteins 0.000 description 1
229950003599 IPSAPIRONE Drugs 0.000 description 1
229960000908 Idarubicin Drugs 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
229960001101 Ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
229960003685 Imatinib mesylate Drugs 0.000 description 1
210000000987 Immune System Anatomy 0.000 description 1
102000018358 Immunoglobulins Human genes 0.000 description 1
108060003951 Immunoglobulins Proteins 0.000 description 1
208000007031 Incontinentia Pigmenti Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
229940102223 Injectable Solution Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000019223 Interleukin-1 receptor family Human genes 0.000 description 1
108050006617 Interleukin-1 receptor family Proteins 0.000 description 1
208000007906 Intestinal Disease Diseases 0.000 description 1
231100000601 Intoxication Toxicity 0.000 description 1
TZJUVVIWVWFLCD-UHFFFAOYSA-N Ipsapirone Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
NICJCIQSJJKZAH-AWEZNQCLSA-N Irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
229950005254 Irofulven Drugs 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
208000001083 Kidney Disease Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
206010023849 Laryngeal papilloma Diseases 0.000 description 1
208000009000 Laryngeal papillomatosis Diseases 0.000 description 1
240000001422 Laurus nobilis Species 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
229940067606 Lecithin Drugs 0.000 description 1
GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
241000589902 Leptospira Species 0.000 description 1
206010059239 Leukaemic retinopathy Diseases 0.000 description 1
210000000265 Leukocytes Anatomy 0.000 description 1
208000000265 Lobular Carcinoma Diseases 0.000 description 1
WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
206010025135 Lupus erythematosus Diseases 0.000 description 1
102100002383 MCL1 Human genes 0.000 description 1
101700031439 MCL1 Proteins 0.000 description 1
102100019155 MDM2 Human genes 0.000 description 1
101700032565 MDM2 Proteins 0.000 description 1
101710034449 MT-CO2 Proteins 0.000 description 1
210000002540 Macrophages Anatomy 0.000 description 1
210000002189 Macula Lutea Anatomy 0.000 description 1
208000002780 Macular Degeneration Diseases 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
206010025425 Maculopathy Diseases 0.000 description 1
229940050906 Magnesium chloride hexahydrate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
206010025650 Malignant melanoma Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
MQXVYODZCMMZEM-ZYUZMQFOSA-N Mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
101700047612 Marf Proteins 0.000 description 1
229960003951 Masoprocol Drugs 0.000 description 1
HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
206010027201 Meningitis aseptic Diseases 0.000 description 1
JABGXPCRNXUENL-UHFFFAOYSA-N Mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
208000004197 Mesenchymoma Diseases 0.000 description 1
229960004635 Mesna Drugs 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
108020004999 Messenger RNA Proteins 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
230000036091 Metabolic activity Effects 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
RQNMYNYHBQQZSP-UHFFFAOYSA-M Methylmagnesium chloride Chemical compound C[Mg]Cl RQNMYNYHBQQZSP-UHFFFAOYSA-M 0.000 description 1
VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
229960003539 Mitoguazone Drugs 0.000 description 1
229960004857 Mitomycin Drugs 0.000 description 1
229960000350 Mitotane Drugs 0.000 description 1
229960001156 Mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 1
208000003627 Muscular Dystrophy Diseases 0.000 description 1
206010028576 Myeloproliferative disease Diseases 0.000 description 1
210000004413 Myocytes, Cardiac Anatomy 0.000 description 1
240000001307 Myosotis scorpioides Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
NEPLDSFRUXZNGL-UHFFFAOYSA-N N1C=CC=C1.O1C(=CC(=O)C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound N1C=CC=C1.O1C(=CC(=O)C2=CC=CC=C12)C1=CC=CC=C1 NEPLDSFRUXZNGL-UHFFFAOYSA-N 0.000 description 1
229940052665 NADH Drugs 0.000 description 1
102100002692 NFKB1 Human genes 0.000 description 1
101700086102 NFKB1 Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102100020079 NPM1 Human genes 0.000 description 1
210000003928 Nasal Cavity Anatomy 0.000 description 1
229950007221 Nedaplatin Drugs 0.000 description 1
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
206010029149 Nephropathy Diseases 0.000 description 1
206010029151 Nephropathy Diseases 0.000 description 1
210000000440 Neutrophils Anatomy 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
210000000633 Nuclear Envelope Anatomy 0.000 description 1
210000004492 Nuclear Pore Anatomy 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000002488 Nucleoplasmins Human genes 0.000 description 1
108060005597 Nucleoplasmins Proteins 0.000 description 1
229910004749 OS(O)2 Inorganic materials 0.000 description 1
229940049964 Oleate Drugs 0.000 description 1
210000004248 Oligodendroglia Anatomy 0.000 description 1
229920000272 Oligonucleotide Polymers 0.000 description 1
HYFHYPWGAURHIV-UHFFFAOYSA-N Omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
210000004279 Orbit Anatomy 0.000 description 1
210000001672 Ovary Anatomy 0.000 description 1
206010068786 Overlap syndrome Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
206010070594 PFAPA syndrome Diseases 0.000 description 1
229940030490 PROGESTOGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
229960001592 Paclitaxel Drugs 0.000 description 1
206010033364 Paget's disease of nipple Diseases 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000010403 Panophthalmitis Diseases 0.000 description 1
241000282322 Panthera Species 0.000 description 1
210000003695 Paranasal Sinuses Anatomy 0.000 description 1
208000006551 Parasitic Disease Diseases 0.000 description 1
206010034038 Parotitis Diseases 0.000 description 1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
229940049954 Penicillin Drugs 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229960002340 Pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
241001442654 Percnon planissimum Species 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
206010057267 Periphlebitis Diseases 0.000 description 1
210000004303 Peritoneum Anatomy 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
QGVLYPPODPLXMB-MEQJGUAMSA-N Phorbol Natural products O=C1C(C)=C[C@H]2[C@]3(O)[C@H](C)[C@H](O)[C@@]4(O)C(C)(C)[C@@H]4[C@@H]3C=C(CO)C[C@]12O QGVLYPPODPLXMB-MEQJGUAMSA-N 0.000 description 1
229950010765 Pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
210000004011 Plasma Cells Anatomy 0.000 description 1
229960003171 Plicamycin Drugs 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
239000004698 Polyethylene (PE) Substances 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 description 1
229920001451 Polypropylene glycol Polymers 0.000 description 1
241001417524 Pomacanthidae Species 0.000 description 1
UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
229960004293 Porfimer Sodium Drugs 0.000 description 1
229940069338 Potassium Sorbate Drugs 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229940095055 Progestogen systemic hormonal contraceptives Drugs 0.000 description 1
210000002307 Prostate Anatomy 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
229950008679 Protamine sulfate Drugs 0.000 description 1
102000014961 Protein Precursors Human genes 0.000 description 1
108010078762 Protein Precursors Proteins 0.000 description 1
229940034080 Provenge Drugs 0.000 description 1
206010037162 Psoriatic arthropathy Diseases 0.000 description 1
208000002815 Pulmonary Hypertension Diseases 0.000 description 1
229940117820 Purinethol Drugs 0.000 description 1
208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
229940083082 Pyrimidine derivatives acting on arteriolar smooth muscle Drugs 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010064714 Radiation retinopathy Diseases 0.000 description 1
AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
229940100618 Rectal Suppository Drugs 0.000 description 1
206010038111 Recurrent cancer Diseases 0.000 description 1
208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
206010038428 Renal disease Diseases 0.000 description 1
229920001785 Response element Polymers 0.000 description 1
206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
210000001927 Retinal Artery Anatomy 0.000 description 1
208000004644 Retinal Vein Occlusion Diseases 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
102000026486 Retinoid X Receptor alpha Human genes 0.000 description 1
108010066463 Retinoid X Receptor alpha Proteins 0.000 description 1
206010038932 Retinopathy Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
206010072736 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
108010001645 Rituximab Proteins 0.000 description 1
VHXNKPBCCMUMSW-FQEVSTJZSA-N Rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
229950009213 Rubitecan Drugs 0.000 description 1
101710033747 S6 Proteins 0.000 description 1
102100015935 SMYD3 Human genes 0.000 description 1
101700058247 SMYD3 Proteins 0.000 description 1
LBGFKUUHOPIEMA-PEARBKPGSA-N Sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 description 1
229950006896 Sapacitabine Drugs 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
229950000055 Seliciclib Drugs 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000168254 Siro Species 0.000 description 1
208000000927 Sleep Apnea Syndrome Diseases 0.000 description 1
206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
108020004459 Small Interfering RNA Proteins 0.000 description 1
240000002825 Solanum vestissimum Species 0.000 description 1
235000018259 Solanum vestissimum Nutrition 0.000 description 1
229940075582 Sorbic Acid Drugs 0.000 description 1
210000000278 Spinal Cord Anatomy 0.000 description 1
208000008513 Spinal Cord Injury Diseases 0.000 description 1
231100000632 Spindle poison Toxicity 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
208000006045 Spondylarthropathy Diseases 0.000 description 1
206010052775 Spondyloarthropathy Diseases 0.000 description 1
206010041823 Squamous cell carcinoma Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
208000003265 Stomatitis Diseases 0.000 description 1
229960005322 Streptomycin Drugs 0.000 description 1
229960001052 Streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
206010042211 Stress disease Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010042316 Subarachnoid haemorrhage Diseases 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
102100009534 TNF Human genes 0.000 description 1
101710040537 TNF Proteins 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
229960001278 Teniposide Drugs 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
229960005353 Testolactone Drugs 0.000 description 1
229960003604 Testosterone Drugs 0.000 description 1
229960003433 Thalidomide Drugs 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
229960005454 Thioguanine Drugs 0.000 description 1
229960001196 Thiotepa Drugs 0.000 description 1
FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
206010044008 Tonsillitis Diseases 0.000 description 1
210000004746 Tooth Root Anatomy 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
108010010691 Trastuzumab Proteins 0.000 description 1
208000005765 Traumatic Brain Injury Diseases 0.000 description 1
PXSOHRWMIRDKMP-UHFFFAOYSA-N Triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
229960004560 Triaziquone Drugs 0.000 description 1
GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
UMKFEPPTGMDVMI-UHFFFAOYSA-N Trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
101710036359 UL47 Proteins 0.000 description 1
101700002686 US13 Proteins 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
RSJKGSCJYJTIGS-UHFFFAOYSA-N Undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N Undecylic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
229940035893 Uracil Drugs 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
210000001215 Vagina Anatomy 0.000 description 1
ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
229940099259 Vaseline Drugs 0.000 description 1
210000003462 Veins Anatomy 0.000 description 1
YTZALCGQUPRCGW-ZSFNYQMMSA-N Verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
229960003895 Verteporfin Drugs 0.000 description 1
229960003048 Vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229960004528 Vincristine Drugs 0.000 description 1
229960004355 Vindesine Drugs 0.000 description 1
NMDYYWFGPIMTKO-ZSRSGXGDSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@@H]2C[C@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-ZSRSGXGDSA-N 0.000 description 1
210000002845 Virion Anatomy 0.000 description 1
229960000237 Vorinostat Drugs 0.000 description 1
WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
241000710886 West Nile virus Species 0.000 description 1
101700065639 XPO1 Proteins 0.000 description 1
102100003679 YAP1 Human genes 0.000 description 1
108060009539 YAP1 Proteins 0.000 description 1
AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
125000005396 acrylic acid ester group Chemical group 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001154 acute Effects 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
201000011101 acute retrobulbar neuritis Diseases 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
230000001058 adult Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
108010081667 aflibercept Proteins 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910001884 aluminium oxide Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229920002892 amber Polymers 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960002550 amrubicin Drugs 0.000 description 1
229960001694 anagrelide Drugs 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
108010072788 angiogenin Proteins 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
238000011122 anti-angiogenic therapy Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002429 anti-coagulation Effects 0.000 description 1
230000003110 anti-inflammatory Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
229960002594 arsenic trioxide Drugs 0.000 description 1
GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
230000001174 ascending Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229950010993 atrasentan Drugs 0.000 description 1
229960003005 axitinib Drugs 0.000 description 1
RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229960002707 bendamustine Drugs 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000008359 benzonitriles Chemical class 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
229960000626 benzylpenicillin Drugs 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
229960002938 bexarotene Drugs 0.000 description 1
GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000746 body regions Anatomy 0.000 description 1
201000008873 bone osteosarcoma Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
229960003736 bosutinib Drugs 0.000 description 1
201000005216 brain cancer Diseases 0.000 description 1
201000010983 breast ductal carcinoma Diseases 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
229940025250 camphora Drugs 0.000 description 1
239000010238 camphora Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
229960002115 carboquone Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000002317 cardiac myocyte Anatomy 0.000 description 1
201000008031 cardiomyopathy Diseases 0.000 description 1
229960003261 carmofur Drugs 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000035569 catabolism Effects 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular Effects 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
239000002561 chemical irritant Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
201000006082 chickenpox Diseases 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal Effects 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
229960000928 clofarabine Drugs 0.000 description 1
ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000005037 combinatorial chemistry Methods 0.000 description 1
201000009230 common cold Diseases 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
201000009541 complex regional pain syndrome Diseases 0.000 description 1
239000000306 component Substances 0.000 description 1
201000006233 congestive heart failure Diseases 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
201000007717 corneal ulcer Diseases 0.000 description 1
230000002596 correlated Effects 0.000 description 1
201000010549 croup Diseases 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
RRKODOZNUZCUBN-UHFFFAOYSA-N cycloocta-1,3-diene Chemical compound C1CCC=CC=CC1 RRKODOZNUZCUBN-UHFFFAOYSA-N 0.000 description 1
URYYVOIYTNXXBN-UHFFFAOYSA-N cyclooctene Chemical compound [CH]1[CH]CCCCCC1 URYYVOIYTNXXBN-UHFFFAOYSA-N 0.000 description 1
239000004913 cyclooctene Substances 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
SDYFTMROHZCYSK-UHFFFAOYSA-N cyclopropylhydrazine;hydrochloride Chemical compound Cl.NNC1CC1 SDYFTMROHZCYSK-UHFFFAOYSA-N 0.000 description 1
201000003883 cystic fibrosis Diseases 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
229960003603 decitabine Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
229960005052 demecolcine Drugs 0.000 description 1
229960002923 denileukin diftitox Drugs 0.000 description 1
108010017271 denileukin diftitox Proteins 0.000 description 1
229920003013 deoxyribonucleic acid Polymers 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
231100000080 dermatitis contact Toxicity 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108010037444 diisopropylglutathione ester Proteins 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
231100001003 eczema Toxicity 0.000 description 1
229960001776 edrecolomab Drugs 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229960000925 efaproxiral Drugs 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
229940046079 endocrine therapy drugs Progestogens Drugs 0.000 description 1
239000007920 enema Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
201000006608 esophagus squamous cell carcinoma Diseases 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
QWVNYBWNXRRADG-WAYWQWQTSA-N ethyl (Z)-3-[5-(2-amino-5-chlorophenyl)-1,2,4-triazol-1-yl]prop-2-enoate Chemical compound CCOC(=O)\C=C/N1N=CN=C1C1=CC(Cl)=CC=C1N QWVNYBWNXRRADG-WAYWQWQTSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000003176 fibrotic Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
125000001153 fluoro group Chemical class F* 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960004783 fotemustine Drugs 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
238000007710 freezing Methods 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037240 fusion proteins Human genes 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
229960000578 gemtuzumab Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
235000005035 ginseng Nutrition 0.000 description 1
235000008434 ginseng Nutrition 0.000 description 1
231100000852 glomerular disease Toxicity 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000003862 health status Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
201000010238 heart disease Diseases 0.000 description 1
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000003667 hormone antagonist Substances 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical class C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 1
YVJRCWCFDJYONJ-UHFFFAOYSA-N hydroperoxymethylbenzene Chemical compound OOCC1=CC=CC=C1 YVJRCWCFDJYONJ-UHFFFAOYSA-N 0.000 description 1
230000001631 hypertensive Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
201000008319 inclusion body myositis Diseases 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000000968 intestinal Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
201000008255 invasive lobular carcinoma Diseases 0.000 description 1
238000009114 investigational therapy Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000002427 irreversible Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000010977 jade Substances 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
229960004891 lapatinib Drugs 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229960004942 lenalidomide Drugs 0.000 description 1
230000003902 lesions Effects 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
230000000670 limiting Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
201000004044 liver cirrhosis Diseases 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
229960003538 lonidamine Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
229950005239 lucanthone Drugs 0.000 description 1
201000003265 lymphadenitis Diseases 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229950008612 mannomustine Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000005505 measles Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229920002106 messenger RNA Polymers 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
229960005485 mitobronitol Drugs 0.000 description 1
MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000006011 modification reaction Methods 0.000 description 1
235000016768 molybdenum Nutrition 0.000 description 1
150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
238000002625 monoclonal antibody therapy Methods 0.000 description 1
MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
201000009251 multiple myeloma Diseases 0.000 description 1
239000010813 municipal solid waste Substances 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
201000003793 myelodysplastic syndrome Diseases 0.000 description 1
230000002071 myeloproliferative Effects 0.000 description 1
201000002481 myositis Diseases 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000005445 natural product Substances 0.000 description 1
229930014626 natural products Natural products 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
210000003867 nerve cell Anatomy 0.000 description 1
210000004255 neuroglia Anatomy 0.000 description 1
210000002569 neurons Anatomy 0.000 description 1
230000002981 neuropathic Effects 0.000 description 1
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960001420 nimustine Drugs 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
230000006849 nucleocytoplasmic transport Effects 0.000 description 1
108010025568 nucleophosmin Proteins 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
229940005619 omacetaxine Drugs 0.000 description 1
229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960001744 pegaspargase Drugs 0.000 description 1
108010001564 pegaspargase Proteins 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
230000000737 periodic Effects 0.000 description 1
229940083251 peripheral vasodilators Purine derivatives Drugs 0.000 description 1
230000000505 pernicious Effects 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
201000001369 pharyngoconjunctival fever Diseases 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
229930002200 phorbol Natural products 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
235000015108 pies Nutrition 0.000 description 1
125000004193 piperazinyl group Chemical class 0.000 description 1
125000005936 piperidyl group Chemical class 0.000 description 1
229960001221 pirarubicin Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
231100000773 point of departure Toxicity 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002496 poly(ether sulfone) Polymers 0.000 description 1
229920003208 poly(ethylene sulfide) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229960000688 pomalidomide Drugs 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
230000003405 preventing Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
201000001263 psoriatic arthritis Diseases 0.000 description 1
238000005086 pumping Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
RCIGDGBXEMECGY-UHFFFAOYSA-N pyridin-3-ylhydrazine Chemical compound NNC1=CC=CN=C1 RCIGDGBXEMECGY-UHFFFAOYSA-N 0.000 description 1
KRTLKPFLTASKCG-UHFFFAOYSA-N pyridin-4-ylhydrazine Chemical compound NNC1=CC=NC=C1 KRTLKPFLTASKCG-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
230000002285 radioactive Effects 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
229960002185 ranimustine Drugs 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000000452 restraining Effects 0.000 description 1
230000002207 retinal Effects 0.000 description 1
235000020945 retinal Nutrition 0.000 description 1
239000011604 retinal Substances 0.000 description 1
201000011056 retinal disease Diseases 0.000 description 1
201000011195 retinal edema Diseases 0.000 description 1
239000000790 retinal pigment Substances 0.000 description 1
201000001949 retinal vasculitis Diseases 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
101710004466 rgy Proteins 0.000 description 1
101710030364 rgy1 Proteins 0.000 description 1
101710030359 rgy2 Proteins 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
238000010898 silica gel chromatography Methods